Payment overview · 2025
General Payments
$98.36
6 reported records · 5 companies
Healthcare provider profile · identity verified
Roberto A Duran, MD
Allopathic & Osteopathic Physicians|Family Medicine · EAGLE PASS, TX · NPI 1215086749
Verified facts
What the public records show
CMS Open Payments records show Roberto A Duran, MD received $98.36 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 33.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abilify Maintena by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.22 | 33.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.46 | 20.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.02 | 17.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.15 | 14.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.51 | 13.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $98.36 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
104 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
154 | 31 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 688 | 234 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 469 | 378 |
| Losartan Potassium | Losartan Potassium | 446 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 441 | 140 |
| Metformin Hcl | Metformin Hcl | 413 | 147 |
| Tramadol Hcl | Tramadol Hcl | 389 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 373 | 120 |
| Alendronate Sodium | Alendronate Sodium | 328 | 107 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 318 | 317 |
| Omeprazole | Omeprazole | 296 | 100 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 276 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 76 |
| Carvedilol | Carvedilol | 246 | 86 |
| Glimepiride | Glimepiride | 230 | 81 |
| Gabapentin | Gabapentin | 218 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 191 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 184 | 61 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 180 | 57 |
| Cilostazol | Cilostazol | 170 | 60 |
| Simvastatin | Simvastatin | 170 | 57 |
| Alprazolam | Alprazolam | 166 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 52 |
| Ozempic | Semaglutide | 154 | 31 |
| Tradjenta | Linagliptin | 153 | 53 |
| Lisinopril | Lisinopril | 148 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 141 | 45 |
| Celecoxib | Celecoxib | 136 | 41 |
| Montelukast Sodium | Montelukast Sodium | 132 | 42 |
| Farxiga | Dapagliflozin Propanediol | 126 | 35 |
| Famotidine | Famotidine | 124 | 29 |
| Ibuprofen | Ibuprofen | 121 | 36 |
| Januvia | Sitagliptin Phosphate | 104 | 36 |
| Linzess | Linaclotide | 104 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 35 |
| Lovastatin | Lovastatin | 100 | 28 |
| Metformin Hcl Er | Metformin Hcl | 98 | 29 |
| Acarbose | Acarbose | 93 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 31 |
| Valsartan | Valsartan | 86 | 29 |
| Finasteride | Finasteride | 85 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 85 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 29 |
| Sertraline Hcl | Sertraline Hcl | 82 | 32 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 77 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 25 |
| Clonazepam | Clonazepam | 73 | 12 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 70 | 15 |
| Jardiance | Empagliflozin | 69 | 27 |
| Enalapril Maleate | Enalapril Maleate | 68 | 23 |
| Mirtazapine | Mirtazapine | 66 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 26 |
| Ezetimibe | Ezetimibe | 63 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 19 |
| Naproxen | Naproxen | 63 | 15 |
| Pregabalin | Pregabalin | 63 | 17 |
| Atenolol | Atenolol | 61 | 19 |
| Furosemide | Furosemide | 61 | 22 |
| Meclizine Hcl | Meclizine Hcl | 61 | 24 |
| Pentoxifylline | Pentoxifylline | 60 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 18 |
| Eliquis | Apixaban | 58 | 18 |
| Nifedipine Er | Nifedipine | 58 | 21 |
| Trazodone Hcl | Trazodone Hcl | 58 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Potassium Chloride | Potassium Chloride | 52 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 39 |
| Donepezil Hcl | Donepezil Hcl | 45 | 16 |
| Meloxicam | Meloxicam | 45 | 13 |
| Allopurinol | Allopurinol | 41 | 15 |
| Incontrol Pen Needle | Pen Needle, Diabetic | 41 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 40 | 12 |
| Sucralfate | Sucralfate | 38 | 13 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 35 | 14 |
| Carbamazepine | Carbamazepine | 34 | 13 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 34 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Insulin Lispro Junior Kwikpen | Insulin Lispro | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 17 |
| Captopril | Captopril | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $98.36 · 6 records | ABBVIE INC. | CAPVAXIVE, GARDASIL 9, JARDIANCE, LINZESS, REXULTI, ROTATEQ, VAXELIS, VAXNEUVANCE, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error